Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Co-Diagnostics ( (CODX) ).
On October 20, 2025, Co-Diagnostics, Inc. entered into an Equity Distribution Agreement with Maxim Group LLC to establish an at-the-market equity program, allowing the company to offer and sell up to $10 million of its common stock. This move comes after the company terminated a previous agreement with Piper Sandler & Co. and Clear Street LLC, effective September 30, 2025. The new agreement provides flexibility in selling shares, but there is no obligation for the company to sell any shares, and the offering will conclude once the $10 million threshold is reached or the agreement is terminated.
The most recent analyst rating on (CODX) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Co-Diagnostics stock, see the CODX Stock Forecast page.
Spark’s Take on CODX Stock
According to Spark, TipRanks’ AI Analyst, CODX is a Neutral.
Co-Diagnostics faces significant financial challenges, with declining revenues and profitability being the most impactful factors. Technical analysis provides mixed signals, with short-term bearish momentum but some medium-term support. Valuation metrics are unattractive due to negative earnings. Despite some positive developments in product advancement and grant support, the financial difficulties weigh heavily on the overall score.
To see Spark’s full report on CODX stock, click here.
More about Co-Diagnostics
Average Trading Volume: 6,552,049
Technical Sentiment Signal: Sell
Current Market Cap: $15.61M
Find detailed analytics on CODX stock on TipRanks’ Stock Analysis page.